Keller, Paul R.
Pfizer (United States)
2 papers on CoChat
Most cited papers
- Verified
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics
Cancer-related Molecular PathwaysAdvanced Breast Cancer Therapies
Cited by 1,236
- Verified
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry
Heterocyclic Compound Synthesis and BioactivityAdvanced Breast Cancer Therapies
Cited by 513
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free